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High-throughput drug-discovery and mechanistic studies
often require the determination of multiple related crystal
structures that only differ in the bound ligands, point
mutations in the protein sequence and minor conformational
changes. If performed manually, solution and refinement
requires extensive repetition of the same tasks for each
structure. To accelerate this process and minimize manual
effort, a pipeline encompassing all stages of ligand building
and refinement, starting from integrated and scaled diffraction
intensities, has been implemented in Phenix. The resulting
system is able to successfully solve and refine large collections
of structures in parallel without extensive user intervention
prior to the final stages of model completion and validation.
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1. Introduction
One of the most important developments in macromolecular
crystallography over the past 15 years has been the develop-
ment of increasingly automated computational tools that
are significantly more rigorous and self-diagnostic, thereby
decreasing the manual effort involved in structure solution.
Besides general improvements in the capabilities of individual
components of structure-determination pipelines, especially in
the area of automated building (Perrakis et al., 1999; Cowtan,
2006; DiMaio et al., 2006; Terwilliger et al., 2008), a number of
sophisticated pipelines encompassing multiple steps have been
described (Bricogne et al., 2003; Holton & Alber, 2004; Ness et
al., 2004; Panjikar et al., 2005; Keegan & Winn, 2007; Terwil-
liger et al., 2009). These projects are especially focused on
accelerating the early stages of the process (starting either
from raw diffraction images or reduced data), with the goal
of obtaining an unambiguous partial model with minimal user
intervention. Completing the structure is left to the crystallo-
grapher and still remains a largely manual procedure.
In conjunction with these software projects, the productivity
of synchrotron beamlines has progressed, driven by a combi-
nation of brighter radiation sources (Carwardine et al., 2003),
improved detector hardware (Broennimann et al., 2006), and
automated sample mounting and data collection (Karain et al.,
2002; Cipriani et al., 2006; Ueno et al., 2006; Grochulski et al.,
2012). These developments are particularly useful for
structure-based drug discovery, which has prompted pharma-
ceutical companies to build beamlines dedicated to this
purpose. Although these structures encompass a relatively
small number of target proteins deemed to be of therapeutic
utility, the throughput from industrial projects has been esti-
mated at upwards of 10 000 structures per year (Wasserman et
al., 2012). With nearly 600 X-ray crystal structures deposited in
the wwPDB (Berman et al., 2003), the impact of crystal-
lographic studies on the discovery and characterization of the
numerous FDA-approved HIV-1 protease inhibitors is unde-
niable (Wlodawer, 2002). Similar outcomes with other
diseases [e.g. hepatitis C virus (Kanda et al., 2013) and chronic
myelogenous leukemia (Milojkovic & Apperley, 2008)] are on
the way to being realised.
An essential task in structure-based drug discovery is the
placement of functionally relevant ligands into residual
electron density. This has been aided in recent years by a
large number of software packages, including X-LIGAND
(Oldfield, 2001), ARP/wARP (Zwart et al., 2004), LigandFit
(Terwilliger et al., 2006), AFITT (Wlodek et al., 2006), RhoFit
(Global Phasing Ltd) and PrimeX (Bell, Cao et al., 2012). Most
ligand-fitting programs incorporate a local real-space refine-
ment step after the initial placement. To varying degrees, most
also integrate with ligand-parameterization, model-building
and refinement software. However, the very repetitive work-
flow of high-throughput co-crystallography generally remains
a series of discrete steps. Although pharmaceutical companies
often develop proprietary internal pipelines (Kroemer et al.,
2004; Mooij et al., 2006; Davies & Tickle, 2012; Wasserman
et al., 2012), and several independent groups have automated
parts of the process (e.g. Tsai et al., 2013; Sharff et al., 2012),
most of these systems are either integrated with beamline
automation or are not readily available to the broad crystallo-
graphic community.
While many who have been tasked with solving a large
number of crystal structures have developed some means
to solve the nth structure faster and more easily than the
previous n  1 structures out of sheer necessity, the task of
developing a truly generic and robust pipeline is more difficult
than might at first be imagined. It can be relatively straight-
forward to optimize a pipeline for one class of structures;
however, to make it sufficiently robust to handle very different
classes of structures and different qualities of crystallographic
data is non-trivial. Consistent with the Pareto principle (Juran
& Gryna, 1988), or the 80–20 rule, much of the development
effort remains dedicated to making a small number of cases
work. This disparity between effort and percentage success
can be explained by the observation that in the course of a
structure determination, the crystallographer must make
numerous decisions. Many of these decisions rely on his or
her experience and are difficult to codify, especially when a
program is restricted to only the current coordinate and
diffraction data. Even crystallographic steps that are often
taken for granted (e.g. space-group determination and mole-
cular replacement) are difficult to automate universally
because many parameters (e.g. solvent content) are only
guidelines and because of the pervasive extent to which prior
knowledge is naturally and unconsciously utilized.
Here, we describe an integrated pipeline for protein–ligand
structure determination as part of the Phenix suite (Adams et
al., 2010) that was written to specifically target these histori-
cally difficult steps. This pipeline was constructed based on
several previously described programs that were intentionally
designed around a common framework with future automa-
tion in mind (Terwilliger et al., 2006; McCoy et al., 2007;
Moriarty et al., 2009; Afonine et al., 2012). Considerable effort
was made to codify the decision-making steps used by
experienced crystallographers as they weighed intermediate
results against the relevant guideline(s). Starting from
processed data, a closely related molecular-replacement
search model and basic chemical information about the target
ligand, the program is capable of producing high-quality and
nearly complete structures with minimal user intervention in
many cases. Integrated validation tools (Chen et al., 2010)
assist the user with quality control and completion of the
resulting structures. The pipeline was benchmarked against
several collections of structure-based drug-discovery protein–
ligand complexes and a representative sample of the Iridium
database of curated protein–ligand structures (Warren et al.,
2012). In order to ensure no advantage from hindsight, the
pipeline was given the same search model and structure
factors as used for the published structure determination. The
pipeline is able to solve many ligand-bound structures and in
some cases can produce results that rival, if not exceed, those
of the original deposition.
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Figure 1
A schematic of the pipeline workflow. Optional modules are highlighted
with dashed borders and multiprocessor-aware modules are designated
by gray shading. The Coot steps are only invoked in interactive mode.
2. Methods
2.1. Basic design
The software (phenix.ligand_pipeline) is implemented in
Python and is designed to be entirely self-contained within the
Phenix suite with no external dependencies. An overview of
the steps taken is shown in Fig. 1. The individual steps were
encapsulated in modular code so they could be used iteratively
and in different workflows. The approach could be extended
in the future to adopt a more general-purpose automation
framework where components could be removed or added
(Tsai et al., 2013).
In most cases, the program runs with minimal configuration.
The only mandatory inputs are processed data (scaled inten-
sities or amplitudes, in any commonly used format), a starting
model for molecular replacement (or, if isomorphous, mole-
cular substitution) and a source of ligand geometry informa-
tion such as a SMILES string or file (Weininger, 1988), a
MOL2 or restraints CIF file, or a PDB residue code that
directs eLBOW (Moriarty et al., 2009) to use the entry in the
Chemical Components Dictionary (Henrick et al., 2008). If a
directory path is given as input, the program attempts to
automatically determine the appropriate input files by scan-
ning the directory contents. Although the processing of raw
diffraction images is currently outside the scope of Phenix, the
program could be extended to run in conjunction with existing
automated data-processing pipelines (Winter, 2010; Vonrhein
et al., 2011).
2.1.1. Data setup and analysis. An initial step converts the
diffraction data to amplitudes in MTZ format as necessary.
Rfree flags are either imported or generated if absent.
Following this conversion, the data quality is assessed using
phenix.xtriage (Zwart et al., 2005) to identify possible twinning
and to determine a suitable resolution cutoff if desired. If the
number of MR search copies is not defined, it is estimated
based on the Matthews coefficient.
2.1.2. Molecular replacement. Although many ligand co-
crystal structures are effectively isomorphous with the native
structure and/or each other, the procedure runs Phaser
(McCoy et al., 2007) by default to ensure correct placement
of the protein. The search model is modified by Sculptor
(Bunko´czi & Read, 2011) to match the input sequence as
closely as possible, without completing missing side chains;
common modified amino acids such as phosphotyrosine are
left in place if in agreement with the sequence. The default
settings for the MR_AUTO mode are used, except that non-
water heteroatoms present in the search model are retained at
full occupancy. If desired, the MR solution can be mapped to
the same frame of reference as an isomorphous structure using
phenix.find_alt_orig_sym_mate (Oeffner et al., 2012).
2.1.3. Ligand generation. If the input ligand information
does not contain full geometry restraints, the molecular
geometry is calculated by eLBOW and output as restraints in
CIF format, coordinates in PDB format and Python pickle
files. Currently, the desired stereoisomer must be explicitly
requested in the case of chiral ligands; although eLBOW is
capable of enumerating chiral centers, discrimination between
enantiomers will require additional computational decision-
making as part of the fitting procedure. Although the default
optimization is usually sufficient for ligand placement, the
semi-empirical AM1 quantum-mechanical method is also
available and may yield improved geometries and parameters.
2.1.4. Initial refinement and rebuilding. Once the model is
correctly placed, phenix.refine (Afonine et al., 2012) is run
using the individual coordinate (in both real and reciprocal
space) and atomic displacement parameter (ADP) refinement
strategies. If Phaser was not run previously, rigid-body
refinement will be performed with each protein chain as a
separate group. A resolution-dependent parameterization is
used for determining the ADP type and several other options,
including automated rotamer fitting and solvent updating.
Simulated annealing is available as an option. The user may
also specify custom settings in a parameter file to be passed to
phenix.refine. Weight optimization is not normally used at this
stage, as rapid convergence is considered more important than
obtaining an ideal geometry and minimizing overfitting.
Following the initial refinement the model is further
processed to remove atoms that may interfere with ligand
binding, including waters and side chains with poor fit to
density. If the Rfree is greater than a specified cutoff after
refinement, indicating severely misfitted regions beyond the
radius of convergence of refinement, the AutoBuild wizard
(Terwilliger et al., 2008) is used to apply a more aggressive
strategy for improving the model (with the default rebuild-in-
place mode, which will preserve the input atoms). We have
found empirically that an Rfree cutoff of 0.32 is appropriate in
most cases, but this can be adjusted by the user.
2.1.5. Ligand fitting. The LigandFit wizard (Terwilliger et
al., 2006) is currently used for placing the target ligand
(without H atoms) in the mFo  DFc map calculated with
waters removed, using the geometry specified by eLBOW,
which produces both the restraints and coordinates in an
efficient manner. The difference map may optionally be
improved using an automated maximum-entropy procedure
(Gull & Daniel, 1978), which has the effect of extending it to
higher resolution; however, by default maps are truncated at
1.5 A˚, since the additional detail beyond this was found to not
be beneficial (and occasionally to be detrimental) for ligand
fitting owing to lower correlation coefficients even when the
placement was correct. The number of ligand copies to search
for is assumed to be the same as the number of copies of the
search model, although this also may be specified by the user.
The pipeline uses a slightly more rigorous, but slower, set of
options than the settings for the default LigandFit procedure
to ensure comprehensive sampling of conformations. A cutoff
of 0.7 for the correlation coefficient of the ligand to the map
is required for the placement to be accepted; if the results
for multiple copies are inconsistent, only the highest-scoring
ligands are kept. LigandFit will use NCS relationships to place
ligands if possible, but still filtered by the correlation coeffi-
cient of the density fit. A post-processing step follows this with
more aggressive treatment of the model, removing clashing
protein atoms if a ligand copy generated from NCS operators
agrees with the 2mFo  DFc map. The pipeline is designed to
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easily accommodate alternative methods of ligand placement
(e.g. guided ligand replacement; Klei et al., 2014).
2.1.6. Final refinement. If at least one copy of the ligand can
be placed successfully, a second round of refinement is run
with the following more conservative optimization strategy. If
the resolution is worse than 1.75 A˚, a grid search is used to
determine the optimal weight for the X-ray and stereo-
chemistry/B-factor terms (Afonine et al., 2011). Prior to this,
any amino acids with missing side-chain atoms owing to
pruning or mutations made by Sculptor can optionally be
automatically rebuilt and refined as an additional step. The
placement of elemental ions (Echols et al., in preparation) is
also offered as an option for the refinement step. Heteroatoms
are sorted and grouped with the nearest chain (similar to
structures deposited in the PDB).
Although the models that reach this stage are typically of
high quality and near convergence, user intervention becomes
unavoidable. Poorly fitted regions of the structure are usually
beyond the radius of convergence of simple minimization and
require manual rebuilding, and in many cases additional
ligands from the buffer or crystallization conditions or missing
protein residues may need to be added. As elsewhere in
Phenix (Echols et al., 2012), the entire process is integrated
with validation and visualization tools to streamline and
encourage careful inspection of the structure. In particular,
although the overall correlation coefficient is generally a
reliable indicator of whether the ligand is in the correct
position, the individual molecules still need to be inspected
and, if necessary, corrected to verify good agreement with the
electron density and prior chemical knowledge, as small local
errors may be present. Following refinement, the final model
is validated using the MolProbity suite (Chen et al., 2010) as
implemented in Phenix and a script to view the results in Coot
(Emsley et al., 2010) is generated. A simple summary file in the
output directory lists each placed ligand and its fit to the
electron density as judged by several metrics including overall
CC and difference map peaks, with a warning if ligand
placement was not entirely successful or if the density metrics
suggest (partial) misfitting.
2.2. Error handling
The pipeline terminates at several logical points if relevant
quality thresholds are not satisfied. If the Rfree after the initial
refinement is above 0.5, indicating an incorrect or incomplete
MR solution or a model outside the normal range of conver-
gence, no further building or ligand placement is performed.
The cutoff of 0.7 for the ligand–map CC minimizes the risk of
false positives, which often go undetected even with manual
building (Pozharski et al., 2013). This may exclude some
ligands that are in fact largely correct but include disordered
fragments or are present at partial occupancy. The individual
output files from LigandFit are available for manual inspec-
tion if desired. The program does not attempt to reinterpret
ligand placements that pass the initial cutoff, but a post-
refinement validation step calculates statistics versus the final
maps and alerts the user if any values are suspicious. Our tests
(data not shown) indicate that correctly placed ligands usually
have a CC with the 2mFo  DFc map after refinement of at
least 0.9; values below this suggest a partial misfit and/or poor
density for part of the ligand and values below 0.8 often
indicate a false positive.
2.3. Interactive mode
To address the potential limitations of a fully automatic
approach, an interactive mode is available which integrates
with Coot for manual intervention. After the first refinement,
Coot is opened with the refined model and maps displayed.
Additional changes may then be made to the model, after
which the user clicks a button to save the new model and
continue the pipeline. New difference maps are calculated and
passed to LigandFit. Coot is then opened a second time with
a checklist for the individual ligands. Because the associated
restraints CIF file is also loaded into Coot, errors in the
placement can be corrected by torsion-angle rotation and
real-space refinement. Ligands approved by the user are kept
regardless of their initial CC from LigandFit.
2.4. Testing
Because our goal is to automate existing workflows, we have
primarily tested structures from the PDB where the original
MR search model is unambiguously annotated (either in the
PDB header or in the relevant publication). In the majority
of cases we reduced the model to the minimal asymmetric
component, using phenix.xtriage to automatically estimate the
number of copies present in the target structure based on the
solvent content resulting from different numbers of copies.
For ligand input, we either used the canonical SMILES string
specified in the PDB (including exact chirality) or manually
generated a restraints CIF file in eLBOW. Where necessary,
the restraints needed for any additional ligands present in
both the search model and published structure were generated
using eLBOW or phenix.ready_set. The deposited structure
was used as a reference model for phenix.find_alt_orig_sym_
mate as described above and as an atom-name template for
eLBOW, but the model and geometry were not otherwise used
at any stage in the pipeline. For comparison, we also re-refined
the published structures using the same protocol as the final
refinement step of the pipeline. Ligand-atom names were
adjusted as necessary to account for differences in the orien-
tation of chemically symmetric rings (such as phenyl groups)
when calculating r.m.s.d.s, without altering the chemistry or
pose. All structure figures were generated with PyMOL v.1.2.
3. Results
3.1. Representative cases
As examples of high-throughput applications of the pipe-
line, we examined several sets of related structures in detail.
Most of these cases have only a single copy of a ligand and
a small protein model. Run times for these examples with
default settings averaged between 1 and 2 h on a single-
processor core on recent AMD or Intel systems.
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3.1.1. Factor Xa. The protease factor Xa has been a popular
drug-discovery target, with more than 120 structures in the
PDB (usually in complex with anticoagulant drug leads). We
selected a set of five related phenyltriazolinone-bound struc-
tures (Quan et al., 2010), all solved at moderate resolution
(2.2–2.75 A˚). Because one of these, PDB entry 3ffg, does not
have a search model defined in the PDB header, we used the
search model (PDB entry 1fjs) used for entry 2p16 by the same
depositing author (Pinto et al., 2007). The other four structures
were all phased using PDB entry 3ffg as the search model. All
of these structures were completed successfully (Table 1). The
only conformational rearrangement required to accommodate
the ligands was a rotation of the Asp189 side chain, which is
easily accomplished by a combination of gradient minimiza-
tion and rotamer fitting in phenix.refine. The automatically
generated structures are very similar to the deposited models,
with the exception of a flipped phenyltriazolinone moiety in
PDB entry 3kqb.
3.1.2. Thrombin. A slightly larger set of structures from
an academic group is a series of compounds with human
thrombin as a model system for studying the role of solvent
in ligand binding (Biela et al., 2012). The structures were
completed successfully by the pipeline (Table 1) using PDB
entry 1h8d as the starting model (Skordalakes et al., 2001). The
final models for all but one structure have ligand conforma-
tions that are nearly identical to the published models. The
exception, PDB entry 3qwc, differs only by a rotation of the
terminal moiety, and rerunning the job using the maximum-
entropy procedure in map calculations resulted in a correct fit.
A number of details are currently left unmodeled in the
structures produced by the pipeline: e.g. covalently attached
N-acetylglucosamine (NAG), other small molecules such as
phosphate and glycerol, misfitted side chains and alternate
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Table 1
Statistics of pipeline runs for selected factor Xa (Quan et al., 2010),
thrombin (Biela et al., 2012) and HIV-1 protease (Klei et al., 2007) data
sets.
Unless specified by ‘C’ for custom, default parameters were used. For custom
runs, only one attempt was made to adjust the parameters (e.g. lowering the
CC cutoff for accepting ligand placements) and to get the refinement to
complete successfully. A ‘P’ for partial indicates that at least one of the copies
of the placed ligand was mostly, but not completely, correct (e.g. it was placed
at the correct location but one or more torsion angles were not set properly).
Protein
PDB
code
dmin
(A˚)
Re-refined
Rwork/Rfree
Pipeline
Rwork/Rfree
Ligand
r.m.s.d. (A˚)
Factor Xa 3ffg 1.54 0.156/0.186 0.159/0.197 0.25
3kqb 2.25 0.170/0.193 0.175/0.202 1.21
3kqc 2.20 0.165/0.197 0.172/0.209 0.93
3kqd 2.75 0.189/0.238 0.202/0.239 0.52
3kqe 2.35 0.173/0.213 0.182/0.227 0.77
Thrombin 3p17 1.43 0.126/0.157 0.140/0.161 0.93
3qto 1.52 0.144/0.158 0.156/0.172 0.06
3qtv 1.63 0.144/0.164 0.153/0.174 0.07
3qwc 1.74 0.145/0.168 0.152/0.177 P 3.69
0.151/0.173 C 0.08
3qx5 1.35 0.123/0.146 0.136/0.153 0.06
3sha 1.52 0.145/0.169 0.157/0.178 0.08
3shc 1.90 0.157/0.179 0.162/0.164 0.20
3si3 1.55 0.142/0.164 0.151/0.175 0.17
3si4 1.27 0.134/0.155 0.144/0.163 0.07
3sv2 1.30 0.136/0.163 0.150/0.172 0.09
HIV-1 protease 2fxd 1.60 0.181/0.205 0.216/0.247 0.13
2fxe 1.80 0.165/0.199 0.179/0.199 0.33†
† Single conformation only.
Figure 2
Comparison of refined model and ligand binding between published
(purple) and pipeline (yellow) results for atazanavir-bound HIV-1
protease structures (Klei et al., 2007). The electron density prior to
ligand placement is displayed as a gray mesh for the 2mFo  DFc map
(contoured at 1.0) and as green and red meshes for the mFo  DFc map
(contoured at3.0). For clarity, only density within a 1.5 A˚ radius of the
ligand is displayed. (a) PDB entry 2fxe; active site of inhibitor-resistant
mutant showing published symmetric binding of the inhibitor (with the
second conformation colored blue). (b) PDB entry 2fxd; active site of the
cleavage-resistant mutant. (c) Overall structure of the cleavage-resistant
mutant at the end of refinement (using chain A of 2fxe as the starting
model), illustrating the remaining differences in conformation and
missing atoms. The red arrow indicates the loop comprising residues
80–83 in chain B.
conformations. However, a pair of sodium ions present in the
published models were automatically built by phenix.refine in
eight of the structures using a novel identification procedure
(Echols et al., in preparation).
3.1.3. HIV-1 protease. Human immunodeficiency virus
(HIV) protease was one of the earliest and most successful
targets of structure-based drug discovery (Wlodawer, 2002).
Because of its clinical importance and the rapid mutation of
the viral genome, which often leads to drug resistance, more
than 500 structures of various forms of the protein have been
deposited in the PDB. Inhibitors typically bind in the cleft
formed by the dimer, often in two symmetric poses. Because
of this behavior and the frequency of mutations that affect
binding, it poses a more challenging test case for automation.
We tested the pipeline on a pair of mutant forms bound to the
inhibitor atazanavir (Klei et al., 2007). One of these, desig-
nated the inhibitor-resistant mutant (PDB entry 2fxe), is
similar to the wild-type structure and binds atazanavir
symmetrically; this structure was phased using PDB entry 1hvi
(Hosur et al., 1994). The refined structure was subsequently
used to phase the cleavage-resistant mutant (PDB entry 2fxd),
which binds the inhibitor in a single orientation and exhibits
more local conformational differences relative to the wild
type.
Because the SMILES string for atazanavir in the PDB
(residue code DR7) does not specify the chirality of one of the
N atoms, we generated the molecular structure manually in
eLBOW. Although LigandFit was able to find both confor-
mations of the ligand in PDB entry 2fxe (LigandFit typically
finds five candidate placements of a ligand), only the one with
the highest CC is selected (Fig. 2a). Either the protease
monomer or the assembled dimer can be used for the input
model, with essentially the same outcome. When run with a
monomer the pipeline attempts to find two copies of the
ligand, but since overlapping placements are not allowed it
continues with the single copy and generates a warning at the
end of the run. Aside from the lack of a second conformer in
PDB entry 2fxe, the automatic ligand placements for both
structures are nearly identical to the deposited models (Figs. 2a
and 2b). The refined model for PDB entry 2fxe is in very close
agreement with the published model and is nearly final aside
from some missing side-chain atoms resulting from point
mutations. Additional manual work is required to complete
the PDB entry 2fxd model (Fig. 2c); in addition to some
incomplete side chains several poorly ordered loops need
inspection and possible deletion, in particular residues 80–83
in chain B. The optional side-chain completion step is able to
restore many of the missing atoms, but the backbone confor-
mation of some residues is sufficiently different to be outside
the radius of convergence of the default refinement protocol.
Both structures also have several additional unmodeled
ligands (acetate, sulfate and glycerol) from the crystallization
buffer.
3.2. Benchmarking against a diverse test set
As a more thorough measure of performance, we ran the
pipeline on a set of manually curated structures used for
testing ligand-docking software (the Iridium-HT test set;
http://www.eyesopen.com/iridium), which have been filtered
to contain only ligands whose chemical identity is unambig-
uous with good fit to electron density and no geometrical
problems (Warren et al., 2012). We selected 36 structures
representing 31 unique proteins (Supplementary Table S11)
for which a single search model can be unambiguously iden-
tified from the PDB header. In each case a single ligand
species of interest is bound, although some structures also
contain additional physiologically relevant ligands that are
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Table 2
Summary of the phenix.ligand_pipeline results for the Iridium test set
(listed in alphabetical order by PDB code).
The re-refined Rwork/Rfree values for the deposited models were generated
using the same protocol as the final stage of the pipeline. The placed/present
column gives the number of copies of the ligand placed out of the number of
copies in the asymmetric unit. All copies of the target ligand were successfully
placed in the first attempt for 21 of the 36 test cases; another five were
successful after minor parameter adjustments. Partial solutions were obtained
for six of the problematic cases (designated by italic type).
PDB
code
Re-refined
Rwork/Rfree
Pipeline
Rwork/Rfree
Placed/
present
Ligand
r.m.s.d.(s) (A˚)
1b9v 0.175/0.202 0.200/0.224 1/1 0.65
1br6 0.180/0.224 0.192/0.225 1/1 0.20
1cx2 0.245/0.308 0.250/0.362 0/4 —
1exa 0.169/0.192 0.182/0.213 1/1 0.06
1fcx 0.135/0.167 0.152/0.181 1/1 0.13
1fcz 0.141/0.175 0.157/0.182 1/1 0.08
1fjs 0.158/0.204 0.231/0.255 0/1 —
0.178/0.208 1/1 C 0.59
1g9v 0.141/0.166 0.135/0.171 1/2 0.17
0.136/0.171 2/2 C 0.16, 0.17
1hp0 0.163/0.216 0.173/0.227 2/2 P 0.31, 2.04
1hq2 0.121/0.160 0.134/0.166 1/1 0.10
1hwi 0.165/0.189 0.177/0.198 4/4 0.32–0.44
1hww 0.136/0.167 0.222/0.248 0/1 —
1k3u 0.135/0.162 0.137/0.165 1/1 0.05
1l2s 0.147/0.168 0.168/0.195 2/3 0.15, 0.16
1ml1 0.159/0.208 0.173/0.208 6/6 0.25–0.86
1mq6 0.171/0.221 0.184/0.227 1/1 P 1.36
0.179/0.230 1/1 C 0.68
1mzc 0.146/0.168 0.152/0.168 1/1 P 2.51
1n2j 0.168/0.193 0.185/0.210 2/2 0.10, 0.25
1of1 0.156/0.179 0.175/0.197 2/2 0.11, 0.13
1of6 0.173/0.191 0.208/0.230 8/8 0.11–1.82
1oq5 0.120/0.164 0.231/0.264 0/1 —
0.148/0.188 1/1 C 0.86
1pmn 0.190/0.224 0.218/0.249 1/1 0.53
1q1g 0.156/0.185 0.195/0.214 6/6 0.18–0.63
1q41 0.182/0.195 0.207/0.222 2/2 0.19, 0.30
1qhi 0.214/0.253 0.348/0.403 0/1 —
1r9o 0.162/0.193 0.240/0.284 1/1 0.39
1tt1 0.147/0.171 0.158/0.182 2/2 0.17, 0.19
1u4d 0.187/0.206 0.200/0.219 2/2 P 0.64, 0.67
1unl 0.190/0.214 0.264/0.291 0/1 —
0.246/0.276 1/1 C 0.98
1w1p 0.196/0.230 0.225/0.257 2/2 0.22, 0.30
1w2g 0.177/0.198 0.204/0.221 2/2 0.26, 0.56
1yqy 0.201/0.246 0.351/0.411 0/1 —
1yv3 0.151/0.184 0.169/0.193 1/1 0.19
2ack 0.159/0.185 0.446/0.507 — —
0.165/0.193 1/1 C 0.42
2br1 0.162/0.195 0.170/0.212 1/1 0.33
4cox 0.205/0.30 0.256/0.361 0/4 —
1 Supporting information has been deposited in the IUCr electronic archive
(Reference: LV5055).
present in the starting models (such as haem in PDB entry
1g9v or an ATP analog in PDB entry 1hq2). The ligands vary
widely in size and structure, from pantoate (C6H11O4) to
large drug-like molecules. The pipeline results (Table 2),
when run with default settings, can be summarized as
follows.
(i) 21 (58%) of the structures (PDB entries 1br6, 1b9v, 1exa,
1fcx, 1fcz, 1hq2, 1hwi, 1k3u, 1ml1, 1n2j, 1of1, 1of6, 1pmn, 1q1g,
1q41, 1r9o, 1tt1, 1w1p, 1w2g, 1yv3 and 2br1) worked unam-
biguously with default settings and without intervention;
manual inspection confirmed that the ligand placement was
essentially correct, with only minor disagreements with the
published model (if any). For PDB entry 1of6, we used TYR
(l-tyrosine) as the target residue based on visual inspection of
the deposited model, which is incorrectly labeled as containing
DTY (d-tyrosine).
(ii) PDB entry 1g9v ran successfully, but the number of
copies of ligands was manually specified because the estimated
number of copies of the ligands was incorrect (owing to the
use of the complete hemoglobin tetramer as the search model
versus two ligands bound).
(iii) PDB entry 1l2s also ran successfully, but a third copy
of the ligand bound between the two monomers was not built.
Both active-site ligands were placed identically to the
published structure, but the search for the third failed owing to
the interference of a reoriented Gln side chain in the search
model.
(iv) The pipeline initially failed to solve PDB entry 2ack
owing to the number of copies of the protein being estimated
incorrectly, resulting in an Rfree above the cutoff for contin-
uing; re-running with this explicitly specified was successful
without further intervention.
(v) The pipeline also failed on PDB entry 1oq5 owing to a
poor CC for the ligand density, despite nearly perfect place-
ment (Fig. 3a). Re-running with a more permissive CC cutoff
of 0.6 was successful.
(vi) PDB entry 1mq6 runs to completion, but one section of
the ligand was misfitted owing to ambiguous difference density
(Fig. 3b). A second run with maximum-entropy map treatment
improved the density enough to result in successful placement
(Fig. 3c).
(vii) Two structures, PDB entries 1fjs and 1unl, were both
unsuccessful in the initial run of the pipeline but could be
recovered using the maximum-entropy map calculation (with
the exception of an omitted phenyl ring with poor density in
1unl).
(viii) Two structures, PDB entries 1mzc and 1u4d, finished
without error with one or more ligands placed at the expected
site(s) but either failed to place all copies requested or had
significant errors in the ligand conformation, geometry or
orientation upon visual inspection. Some of these were easily
remedied with minor adjustments in Coot.
(ix) PDB entry 1hww failed because the ligand (swainso-
nine, residue code SWA) consists of a flexible double-ring
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Figure 3
Examples of problematic structures in the Iridium test set. Electron density after the first round of refinement (prior to ligand fitting) is displayed as a
gray mesh for the 2mFoDFc map (contoured at 1.0) and as green and red meshes for themFoDFc map (contoured at3.0). The published model
is shown as purple sticks. Yellow sticks represent the refined model at the end of pipeline execution; orange sticks represent incorrect or rejected ligand
placements. (a) PDB entry 1oq5. The ligand is correctly placed but is rejected because the CC to themFoDFc map falls below the default cutoff of 0.7.
(b) PDB entry 1mq6. The ligand is partially misfitted in the run with default settings (orange sticks) owing to ambiguousmFoDFc density. Filtering the
map with a maximum-entropy procedure results in correct placement (c). (d) Ligand placement in 1hp0, showing deviation from the published structure.
(e) Misfitted ligand in 1hp0 with calcium ion (purple sphere) removed from the starting model.
system that needs to be nonplanar to correctly fit the density, a
degree of freedom not currently explored by LigandFit.
(x) Four structures (PDB entries 1cx2, 1qhi, 1yqy and 4cox)
required more extensive rebuilding of the placed search model
before ligand placement can be successful and were aborted
early.
In summary, these tests indicate that use of the pipeline with
default parameters is likely to be successful in a high
percentage of cases (more than 50%), while the adjustment of
one or more parameters may be required for optimal success
in another 30% of cases. The failure rate owing to pathological
problems with ligand structure or large structural differences
between the search and final model is surprisingly small at
15%.
As the intention of the pipeline is to solve, fit and refine
protein–ligand complexes, the output models are not publi-
cation-ready and require varying degrees of intervention to
replace missing or mutated side chains, rebuild loops or place
additional ligands. In PDB entry 1r9o, for instance, the search
model (PDB entry 1n6b) has only 76% sequence identity and
although ligand placement was successful, there are large
regions on the surface of the protein that have undergone
significant conformational changes and require rebuilding or
deletion. However, in ten cases the final Rfree for a successful
run was within 1% of the re-refined deposited structure and
the geometry quality was consistently high, with aMolProbity
clashscore (Chen et al., 2010) in the single digits for all
successfully completed runs. For many of the examples, it is
likely that an alternative search model is now available that
more closely resembles the crystallized conformation and
would significantly improve convergence; however, we
restricted our tests to using the original search models speci-
fied by the authors.
In most structures in which ligand placement is successful,
the majority of the runtime is accounted for by refinement,
particularly when running weight optimization (Supplemen-
tary Table S2). Running Phaser has a relatively small impact
on the overall runtime, since most MR solutions are unam-
biguous (and in most of the test cases there was only a single
component to place). LigandFit is typically the next most
time-consuming step and this time scales with the number of
copies of the ligand. Because both phenix.refine and LigandFit
can use multiple processor cores on Linux and Macintosh
systems, the elapsed runtime can be significantly shortened on
multi-core systems. However, for large sets of similar struc-
tures such as those discussed in the previous section, proces-
sing multiple data sets in parallel with a single processor per
job may be a significantly more efficient use of computing
resources. If desired, the execution time may be reduced by
disabling weight optimization or by running LigandFit in
‘quick’ mode, at the expense of potentially poorer output
model quality and possible failure of ligand placement.
4. Discussion
The procedure described here has been exercised on hundreds
of structures in the PDB (data not shown) with the goal of
ensuring robust behavior regardless of the ultimate outcome.
Owing to the conservative criteria for evaluating the
LigandFit results, the number of false positives (where a
ligand is placed in the wrong site) has proven to be very low
when used with default parameters. In favorable cases, where
the crystallized protein has minimal changes relative to the
starting model, the final structure is very nearly complete and
can easily be finalized by a single round of manual inspection/
correction and refinement. In several tests, the Rfree was lower
than the published structures. Although this reduction is likely
to be partially owing to improvements in refinement protocols
and/or under-refinement of the original models (Joosten et al.,
2009; Afonine et al., 2012), it does demonstrate the ability of
an automated pipeline to produce relatively high quality
structures. However, we also encountered situations that are
challenging for automation and potentially also for manual
analysis.
Even if the model is extremely accurate and complete,
limitations in map quality can hamper automatic identification
of the correct binding site. In some examples (such as PDB
entry 1oq5 in the Iridium test set), LigandFit places the
ligand(s) correctly but the pipeline rejects these models owing
to a poor CC to the difference map. Alternatively, the
presence of additional unmodeled blobs of difference density
may be fitted preferentially, although such false positives are
usually also rejected based on the CC. These limitations on
sensitivity may make the pipeline less optimal for fragment-
based drug discovery, where the ligands are typically smaller
and bind with lower affinity (and partial occupancy). More
flexibility may be required in the ligand-fitting step for these
structures, such as fitting to the 2mFo  DFc map and using a
more sensitive metric than the CC. However, we found the use
of maximum-entropy maps to be very helpful for several of
the test cases, as it effectively increases the resolution of the
Fourier map and eliminates the bulk of noise (Collins, 1982).
Although the pipeline can be run in a more permissive mode
by decreasing the CC cutoff and/or searching for more copies
of the target ligand, this is not guaranteed to place weakly
defined ligands correctly, as the presence of additional
unmodeled density (for protein or other buffer components)
may frustrate the fitting procedure.
More generally, the use of relatively simplistic geometry
restraints instead of a physically realistic force field may limit
the accuracy of ligand placement in ways that are not easily
detectable by automated procedures. In particular, although
the refinement is performed with explicit H atoms, the lack of
attractive forces or solvation effects may miss fine chemical
detail such as hydrogen bonding and hydrophobic inter-
actions. The use of molecular-mechanics force fields for crys-
tallographic refinement has been shown to yield improved
protein geometry in some cases (Koparde et al., 2011;
Schnieders et al., 2011; Bell, Ho et al., 2012) and it may help
to overcome limitations inherent to low-resolution data sets.
Refinement against a quantum-mechanical potential may also
produce more accurate geometry (Li et al., 2009).
In our tests, the most common reason for failure of ligand
placement was the presence of large conformational differ-
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ences from the true structure, even after the first cycle of
refinement. In many structures, such as protein kinases,
significant conformational changes on the scale of small loops
(e.g. P-loop, DFG loop, activation loop) to entire domains
(e.g. the N-terminal lobe) accompany ligand binding. These
movements are usually outside the range of advanced refine-
ment protocols, such as simulated annealing and the deform-
able elastic network method (Schro¨der et al., 2007; Brunger et
al., 2012), and instead require extensive rebuilding. Although
misfitted residues can be removed from the model, aggressive
pruning often results in ligand placement attempting to utilize
the difference density for the removed protein atoms rather
than only focusing on the true binding site. Because the
current approaches to automated model building in Phenix
(Terwilliger et al., 2008) are aimed at either de novo building
into an experimental map or minor changes to an existing
model, we have not made extensive use of them in the context
of the pipeline. However, targeted application of loop-fitting
methods and inference from related structures may overcome
the rebuilding problem without greatly increasing the runtime.
It is also likely that many structures can be solved more
effectively by automatically testing multiple search models in
molecular replacement (Keegan & Winn, 2007; Long et al.,
2008; Bunko´czi et al., 2013). The large numbers of PDB entries
closely related to most popular drug targets offer an additional
source of structural diversity that could be utilized in
rebuilding.
In challenging cases, use of the interactive mode can effi-
ciently help address problems. Such cases are readily identified
after a first round of automated use of the pipeline. Addi-
tionally, for a series of related compounds, once the structure
of the first protein–ligand complex has been solved, it can be
used as the starting model for the remainder in an automated
manner. Such was the case with the factor Xa structures (Quan
et al., 2010) presented earlier. Irrespective, manual inspection
of the pipeline results (a step that is streamlined by the
generation of a Coot script after refinement) is required to
determine the next steps for structure completion. A final
round of careful validation, remediation of outstanding model
deficiencies and refinement is essential before publication or
deposition. Generally, further improvements in structure
completion (e.g. local model rebuilding, modeling of alternate
conformations, placement of small ions and additional ligands)
are needed to enable researchers to generate deposition-ready
structures in a fully automated manner. The adoption and
diligent use of robust validation tools (Chen et al., 2010; Read
et al., 2011; Pozharski et al., 2013) both during and after the
structure-determination process will continue to be vital as
these approaches become more sophisticated and widespread.
5. Availability
The program phenix.ligand_pipeline is distributed with
source code in the Phenix software suite (http://www.
phenix-online.org) version 1.8.3 or later. The complete suite is
freely available to academic users.
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tium for helpful discussions and the reviewers for their
thoughts on automation and suggestions on presentation. We
are grateful to Gregory Warren and OpenEye Scientific
Software for curating the Iridium test set. This work was
supported by the NIH (Project 1P01 GM063210) and the
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